Pharsight

Drugs that contain Treprostinil

1. Remodulin patents expiration

REMODULIN's oppositions filed in EPO
REMODULIN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(2 months from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil
Dec, 2024

(9 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil
Dec, 2024

(9 months from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil
Dec, 2024

(9 months from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(4 years from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(4 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Mar, 2029

(5 years from now)

Market Authorisation Date: 21 May, 2002

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension co...

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage

REMODULIN family patents

Family Patents

2. Tyvaso patents expiration

TYVASO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(3 years from now)

US10376525 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(3 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(4 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(4 years from now)

US11826327 UNITED THERAP Treatment for interstitial lung disease
Jan, 2042

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Mar 31, 2024

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device; Method of treating pulmonary hypertension associated with interstitial lung dise...

Dosage: SOLUTION;INHALATION

How can I launch a generic of TYVASO before it's drug patent expiration?
More Information on Dosage

TYVASO family patents

Family Patents

3. Tyvaso Dpi patents expiration

TYVASO DPI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(1 year, 5 months from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(3 years from now)

US10772883 UNITED THERAP Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(6 years from now)

US10421729 UNITED THERAP Microcrystalline diketopiperazine compositions and methods
Apr, 2035

(11 years from now)

US11826327 UNITED THERAP Treatment for interstitial lung disease
Jan, 2042

(17 years from now)

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device; Method of treating pulmonary hypertension associated with interstitial lung dise...

Dosage: POWDER;INHALATION

More Information on Dosage

TYVASO DPI family patents

Family Patents